UBE2E1

Ubiquitin-conjugating enzyme E2 E1

675 patent compounds predicted against UBE2E1, 432 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15191832	1.00	20/20
SCHEMBL15191950	1.00	20/20
SCHEMBL15192024	1.00	20/20
SCHEMBL15198144	1.00	20/20
SCHEMBL15198146	1.00	20/20
SCHEMBL15198148	1.00	20/20
SCHEMBL15198150	1.00	20/20
SCHEMBL15198154	1.00	20/20
SCHEMBL15198156	1.00	20/20
SCHEMBL15198158	1.00	20/20
SCHEMBL15198159	1.00	20/20
SCHEMBL15198165	1.00	20/20
SCHEMBL15198171	1.00	20/20
SCHEMBL15198173	1.00	20/20
SCHEMBL15198202	1.00	20/20
SCHEMBL15198210	1.00	20/20
SCHEMBL15198211	1.00	20/20
SCHEMBL15198216	1.00	20/20
SCHEMBL15198218	1.00	20/20
SCHEMBL15198219	1.00	20/20

Germline variants in UBE2E1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full UBE2E1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to UBE2E1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome	PHASE2/PHASE3	NOT_YET_RECRUITING
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)	PHASE3	ACTIVE_NOT_RECRUITING
Study to Compare the Safety and Efficacy of UB-851 and Eprex®	PHASE3	COMPLETED
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine	PHASE3	UNKNOWN
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults	PHASE3	WITHDRAWN
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)	PHASE2	RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety	PHASE2	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)	PHASE1	COMPLETED
A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome	nan	RECRUITING
Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2	nan	NOT_YET_RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Endocrine Disruptors and Life STILe in Breast Cancer Development	nan	UNKNOWN
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a UBE2E1 binder may also engage these)

Protein	Name	Similarity
P52482	—	1.000	P52482 →
P52483	—	1.000	P52483 →
Q96LR5	—	1.000	Q96LR5 →
Q2T9X7	—	0.993	Q2T9X7 →
P52484	—	0.993	P52484 →
Q9LJZ5	—	0.992	Q9LJZ5 →
Q9D1C1	—	0.992	Q9D1C1 →
Q4WLA7	—	0.992	Q4WLA7 →
Q969T4	—	0.992	Q969T4 →
Q6BU36	—	0.991	Q6BU36 →
UBE2B	Ubiquitin-conjugating enzyme E2 B	0.991	landscape →
O00762	—	0.991	O00762 →
Q91W82	—	0.991	Q91W82 →
Q553F3	—	0.990	Q553F3 →
Q6NY82	—	0.989	Q6NY82 →
P52478	—	0.989	P52478 →
Q7ZY08	—	0.988	Q7ZY08 →
Q95017	—	0.988	Q95017 →
Q95044	—	0.988	Q95044 →
Q94490	—	0.988	Q94490 →
P63280	—	0.987	P63280 →
Q2EF73	—	0.987	Q2EF73 →
P63283	—	0.987	P63283 →
Q28CQ4	—	0.987	Q28CQ4 →
P63281	—	0.987	P63281 →
P25153	—	0.987	P25153 →
Q1RMW1	—	0.987	Q1RMW1 →
P63147	—	0.986	P63147 →
B4QHS6	—	0.986	B4QHS6 →
P42746	—	0.986	P42746 →